8BR7 image
Entry Detail
PDB ID:
8BR7
Keywords:
Title:
Discovery of IRAK4 Inhibitors BAY1834845 and BAY1830839
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2022-11-22
Release Date:
2024-01-31
Method Details:
Experimental Method:
Resolution:
2.12 Å
R-Value Free:
0.28
R-Value Work:
0.23
Space Group:
I 2 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Interleukin-1 receptor-associated kinase 4
Mutations:K400A, E401A, E402A
Chain IDs:A (auth: AAA), B (auth: BBB)
Chain Length:298
Number of Molecules:2
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
SEP A SER modified residue
TPO A THR modified residue
Ligand Molecules
Primary Citation

Abstact

Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a critical role in innate inflammatory processes. Here, we describe the discovery of two clinical candidate IRAK4 inhibitors, BAY1834845 (zabedosertib) and BAY1830839, starting from a high-throughput screening hit derived from Bayer's compound library. By exploiting binding site features distinct to IRAK4 using an in-house docking model, liabilities of the original hit could surprisingly be overcome to confer both candidates with a unique combination of good potency and selectivity. Favorable DMPK profiles and activity in animal inflammation models led to the selection of these two compounds for clinical development in patients.

Legend

Protein

Chemical

Disease

Primary Citation of related structures